Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Moore, Kathleen N., O'Malley, David M., Vergote, Ignace, Martin, Lainie P., Gonzalez-Martin, Antonio, Malek, Karim, Birrer, Michael J.Langue:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2018.07.017
Date:
August, 2018
Fichier:
PDF, 580 KB
english, 2018
File converter
Plus de résultats de recherche
More benefits 
